Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy

Digestive and Liver Disease

Volumn 44, Issue 1, 2012, Pages 49-54

  Coppola, Nicola ^a   Pisaturo, Mariantonietta ^a   Guastafierro, Salvatore ^a   Tonziello, Gilda ^a   Sica, Antonello ^a   Iodice, Valentina ^a   Sagnelli, Caterina ^a   Ferrara, Maria Giovanna ^a   Sagnelli, Evangelista ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta   (Italy)

Author keywords

HCV infection; HCV load; Hepatotoxicity; Immunosuppressive diseases; Onco haematological diseases; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC ACTIVE HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; DISEASE EXACERBATION; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 83855160892     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.07.016     Document Type: Article

References (44)

1. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
2. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
3. Hsu C., Hsiung C.A., Su I.J., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
4. Palmore T.N., Shah N.L., Loomba R., et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009, 7:1130-1137.
5. Fukushima N., Mizuta T., Tanaka M., et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009, 20:2013-2017.
6. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
7. Pei S.N., Chen C.H., Lee C.M., et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010, 89:255-262.
8. Koo Y.X., Tan D.S., Tan I.B., et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010, 116:115-121.
9. Marzano A., Angelucci E., Andreone P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
10. Carosi G., Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008, 40:603-617.
11. Vento S., Cainelli F., Mirandola F., et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996, 13:347.
12. Aksoy S., Abali H., Kilickap S., et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006, 28:211-214.
13. Ennishi D., Terui Y., Yokoyama M., et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008, 83:59-62.
14. Hsieh C.Y., Huang H.H., Lin C.Y., et al. Rituximab-induced Hepatitis C Virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol 2008, 26:2584-2585.
15. Pitini V., Sturniolo G., Arrigo C., et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol 2010, 150:116-118.
16. Swerdlow S.H.C.E., Harris N.L., Jaffe E.S., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, p. 218-9.
17. Prati D., Gasbarrini A., Mazzotta F., et al. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST expert opinion meeting. Dig Liver Dis 2010, 42:81-91.
18. Sagnelli E., Coppola N., Scolastico C., et al. HCV genotype and silent HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001, 64:350-355.
19. AIDS Clinical Trials Group Table of grading severity of adult adverse experiences 1996, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
20. Arcaini L., Merli M., Passamonti F., et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010, 85:46-50.
21. Schmidt W.N., Klinzman D., LaBrecque D.R., et al. Direct detection of hepatitis C virus (HCV) RNA from whole blood and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. J Med Virol 1995, 47:153-160.
22. Ratge D., Scheiblhuber B., Nitsche M., et al. High-speed detection of blood-borne hepatitis C virus RNA by single-tube real-time fluorescence reverse-transcription PCR with LightCycler. Clin Chem 2000, 46:1987-1989.
23. Sagnelli E., Coppola N., Pisaturo M., et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009, 49:1090-1097.
24. Halfon P., Bourlie're M., Ouzan D., et al. Occult hepatitis C virus infection revisited with ultrasensitive Real-Time PCR assay. J Clin Microbiol 2008, 46:2106-2108.
25. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
26. Vose J.M., Link B.K., Grossbard M.L., et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:389-397.
27. Schulz H., Klein S.K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100:3115-3120.
28. Ennishi D., Maeda Y., Niitsu N., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116:5119-5125.
29. Petrarca A., Rigacci L., Arena U., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010, 3:335-342.
30. Marignani M., Mangone M., Cox M.C., et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011, 43:139-142.
31. Faggioli P., De Pascale M., Tocci A., et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997, 82:38-42.
32. Fong T.L., Valinluck B., Govindarajan S., et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994, 107:196-199.
33. Ciesek S., Steinmann E., Iken M., et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroentorology 2010, 138:1875-1884.
34. Zeisel M.B., Fofana I., Fafi-Kremer S., et al. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011, 54:566-576.
35. Spengler U., Lechmann M., Irrgang B., et al. Immune responses in hepatitis C virus infection. J Hepatol 1996, 24:20-25.
36. Nelson D.R., Lau J.Y. Pathogenesis of chronic hepatitis C virus infection. Antivir Ther 1998, 3(Suppl. 3):25-35.
37. Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305.
38. Rosen H.R., Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003, 9:35-43.
39. Joyce M., Lorne D., Tyrrell J. The cell biology of hepatitis C virus. Microbes Infect 2010, 12:263-271.
40. Vallisa D., Bernuzzi P., Arcaini L., et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005, 23:468-473.
41. La Mura V., De Renzo A., Perna F., et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 2008, 49:557-563.
42. Mazzaro C., De Re V., Spina M., et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009, 145:255-257.
43. Mele A., Pulsoni A., Bianco E., et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102:996-999.
44. Dal Maso L., Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006, 15:2078-2085.